A New Wave of Bridging Borders: How US-Asia Biotech Leverages Hybrid Models to Rewrite the Rules of the Game

At the 2026 BIO International Convention (BIO 2026), a panel titled “Bridging Borders: How US-Asia Collaboration Is Redefining Global Biotech Deal-Making” offered deep insights into how innovative Asian assets are going global, and how the US and Asia are forging a new generation of global partnerships through complementary strengths. This rising wave is not only accelerating the pace of drug development but is also quietly reshaping how multinational pharmaceutical companies interact with startups.

Historically, Western Big Pharma viewed Asian markets—particularly China—merely as commercial destinations for product sales; today, however, this role has transformed into a vital powerhouse for global innovation. With a massive wave of returnee talent bringing extensive multinational experience back to Asia, the R&D capacity and asset quality of local biotech teams have improved significantly. Consequently, international investors and major pharmaceutical corporations are showing an unprecedented level of interest in innovative technologies originating from Asia.

The Rise of Asian Innovation Captures Global Capital

At this year’s convention, the caliber of scientific research and innovation coming out of Asia stood out as a top focus for investors and major pharmaceutical players alike. A clinical-stage investor from Sofina Investments noted that biotech innovation from Asia has not only grown exponentially in volume over recent years, but the professional caliber of the teams and the quality of their R&D assets are also deeply impressive. 

Asian companies have demonstrated robust, concrete capabilities, particularly in critical therapeutic areas such as:

• Oncology
• Cardiovascular and Metabolic Disease
• Immunology

Much of this explosive momentum is driven by a wave of scientists and senior executives who trained in Europe or the US and gained extensive asset-development experience at global pharmaceutical giants before returning to Asia. Whether launching their own startups or joining local research institutions, they have brought rigorous Western clinical development standards back to their home markets. This has fueled successive waves of globally aligned innovation, giving Asian assets exceptional visibility on the international stage.

External Innovation Becomes Core as Multinationals Shift Strategies

For global pharmaceutical giants like Novartis, external innovation is no longer just a supplement to internal R&D—it has evolved into an indispensable core pillar of their overall corporate strategy. Statistics reveal that a striking 50% of Novartis’s current pipeline value is derived from external collaborations or in-licensing deals, a figure that underscores just how vital sourcing premium external assets is to maintaining a pharma company’s competitive edge.

To swiftly capture the most promising innovative therapies worldwide, multinational pharma companies are actively restructuring their organizations. In the Chinese market, for instance, multinational corporations are not only deploying specialized commercial infrastructure to better capture unmet medical needs, but they are also establishing local R&D organizations. By building deep partnerships with local physicians, scientists, and the broader biotech ecosystem, these companies aim to accelerate the sourcing and integration of premium external innovations from day one.

A New Hybrid Model: Fusing Speed and Resources

Biotech collaboration between the US and Asia is evolving toward a highly efficient “hybrid model“. The experiences of innovative biotech startups like Excalibur Point and Glanis demonstrate that a mature partnership model thrives on combining the distinct strengths of both regions. 

Specifically, companies are leveraging Asia’s “speed advantage”—characterized by high efficiency, low costs, and rapid execution—across several key stages:

• Preclinical trials (PCC)
• Chemistry, Manufacturing, and Controls (CMC)
• Toxicology studies
• Early Phase 1 clinical trials

Once early proof of concept (POC) and safety data are rapidly generated in Asia, biotech companies can package this comprehensive data to engage with international regulatory bodies like the US Food and Drug Administration (FDA). The subsequent Phase 2 and Phase 3 global clinical trials, along with global commercialization, are then handed over to well-resourced, highly experienced Western partners. Together, they can bring innovative medical breakthroughs to patients worldwide at maximum speed.

Quality and Integrity Are Key, Global Patents Cannot Be Overlooked

As the influx of capital drives up valuations for Asian assets, international investors and big pharma companies have become increasingly rigorous and rational during due diligence. Strategic representatives from Novartis frankly noted that they reject far more deals than they accept. The most common hurdles encountered during due diligence typically involve the authenticity and compliance of scientific data, as well as the stringency of CMC processes—areas that represent non-negotiable red lines for biotech companies.

Beyond scientific quality, securing a rigorous global intellectual property strategy (Global IP Strategy) and ensuring Freedom to Operate (FTO) are considered the absolute “lifelines” of cross-border transactions. Experts advise that before seeking cross-border partnerships, startups cannot rely solely on a compelling scientific narrative. They must prepare a comprehensive, battle-tested global patent protection network and ensure that their data is 100% reproducible to successfully win the trust of international pharma giants.

Flexibly Adapting to Regulatory Changes, Mitigating Risks Through Global Footprints

In response to today’s volatile international geopolitical landscape and the introduction of new regulations across various countries—such as the US Biosecurity Act and potential regulatory adjustments regarding offshore corporate structures in China—forward-thinking biotech entrepreneurs and cross-border investors are actively seeking more flexible corporate structures. Many startups are adopting a globalized positioning from day one, refusing to confine themselves to a single market.

For instance, some startups choose to keep their scientific R&D and early clinical trials in Asia to maintain operational efficiency, while establishing corporate and clinical strategy headquarters in the US or Europe. Simultaneously, they are aggressively raising diverse global capital, including from US investors. Guided by legal and regulatory advisors, these companies are demonstrating high levels of transparency and agility, allowing them to nimbly navigate regulatory hurdles and ensure that US-Asia biotech innovation exchange continues uninterrupted by political noise.

Ultimately, the redefinition of global biotech deal-making brought about by US-Asia collaboration represents a return to the healthcare industry’s core mission: combining exceptional global talent, highly efficient systems, and cutting-edge science to deliver life-changing medicines to waiting patients as quickly as possible. As the global biotech industry moves forward hand-in-hand, geographical boundaries are blurring, giving way to a more tightly integrated and highly efficient global innovation network.

Author

Oscar Wu

Fostering knowledge sharing to create a more fluid and transparent information landscape.